Wockhardt (WOCKHARDT) is a global pharmaceutical company headquartered in Mumbai in India. The company is mainly engaged in the manufacturing and marketing of pharmaceutical and biotechnological products. Wockhardt is also involved in new drug discovery and clinical trials and has an active multi-disciplinary R&D program, which involves around 400 scientists. The company has completed Phase I of clinical trials for the new chemical entity - WCK771, which is currently undergoing Phase II clinical trials.
The company has 10 manufacturing plants in India and UK, subsidiaries in US, UK and Brazil, majority- owned companies in South Africa and Mexico and marketing offices in Africa, Russia, Central and South East Asia. Wockhardt has a strong presence in the world`s leading markets, with half of its revenues coming from the US and European markets. The company has been able to expand its global reach by successfully acquiring Pinewood Laboratories and Dumex India. Wockhardt also has manufacturing alliances with many leading pharmaceutical companies such as Aventis, Amylin and Astra Zeneca. It has manufacturing plants in India and the UK, which are certified under USA`s FDA and UK`s MHRA. Financials The company reported rise of 129.75% in consolidated net profit on y-o-y basis to Rs 1.66 billion, while total income climbed 7.30% y-o-y basis to Rs 9.41 billion for the quarter ended March 2011.
The company has 10 manufacturing plants in India and UK, subsidiaries in US, UK and Brazil, majority- owned companies in South Africa and Mexico and marketing offices in Africa, Russia, Central and South East Asia. Wockhardt has a strong presence in the world`s leading markets, with half of its revenues coming from the US and European markets. The company has been able to expand its global reach by successfully acquiring Pinewood Laboratories and Dumex India. Wockhardt also has manufacturing alliances with many leading pharmaceutical companies such as Aventis, Amylin and Astra Zeneca. It has manufacturing plants in India and the UK, which are certified under USA`s FDA and UK`s MHRA. Financials The company reported rise of 129.75% in consolidated net profit on y-o-y basis to Rs 1.66 billion, while total income climbed 7.30% y-o-y basis to Rs 9.41 billion for the quarter ended March 2011.
You
should Trade Less But Trade Accurately & this is Achieved with our Tip.
